Compare iShares MSCI France ETF (EWQ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares MSCI France ETF trades at $41.52 (market cap $330.41M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 14.8× iShares MSCI France ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 57 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| EWQ | TVTX | |
|---|---|---|
Market Cap | $330.41M | $4.88B |
Volume | 244,426 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $67.52 |
52-Week Low | $41.24 | $26.79 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.63, up 0.95% with a bearish technical signal from moving averages. The stock faces European market pressures including ECB rate hikes and energy-driven inflation concerns. Key support sits at $41 with resistance at $42, while RSI indicators show mixed signals between neutral and oversold conditions.
European economic uncertainty and monetary tightening create headwinds, though Goldman Sachs notes resilience in European equities. The stock's technical weakness suggests cautious near-term positioning amid macroeconomic volatility in eurozone markets.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
